605 related articles for article (PubMed ID: 23942539)
1. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
4. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
[TBL] [Abstract][Full Text] [Related]
5. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
[TBL] [Abstract][Full Text] [Related]
6. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
[TBL] [Abstract][Full Text] [Related]
8. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
Zhang H; Li YM; Zhang H; Jin X
Med Oncol; 2007; 24(2):251-8. PubMed ID: 17848752
[TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Lazar A; Jetter A
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
13. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Ciccolini J; Gross E; Dahan L; Lacarelle B; Mercier C
Clin Colorectal Cancer; 2010 Oct; 9(4):224-8. PubMed ID: 20920994
[TBL] [Abstract][Full Text] [Related]
14. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
16. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
[TBL] [Abstract][Full Text] [Related]
17. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
[TBL] [Abstract][Full Text] [Related]
18. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
19. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
20. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
Li LH; Dong H; Zhao F; Tang J; Chen X; Ding J; Men HT; Luo WX; Du Y; Ge J; Tan BX; Cao D; Liu JY
Eur J Cancer; 2013 May; 49(7):1752-60. PubMed ID: 23313143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]